血清基质金属蛋白酶及其抑制剂与肥胖儿童左心室功能的关系

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: Through the study of serum levels of matrix metalloproteinases (MMPs) and its inhibitors (TIMPs), to investigate obesity children at high risk of developing cardiovascular disease impaction on cardiac function. Methods: Blood lipid, systolic pressure, diastolic pressure, blood sugar levels were examined in 30 simple obesity children and 30 normal children; echocardiography (ECHO) test cardiac function; MMPs and TIMPs using enzyme-linked immunosorbent assay (ELISA) detection. Results: ①Blood lipids, systolic pressure, diastolic pressure, blood sugar level in obese children were significantly higher than that in control group (P<0.05); ②Serum levels of MMPs in obese children were significantly higher than that in the control group (P<0.05), while TIMPs levels were lower than the normal control group (P<0.05); ③The left ventricular function changed in obese children, LVEDD, LVESD, LVPWT, IVST levels were significantly higher than that in control group (P<0.05); ④The left ventricular function indicators of obese children were positively correlated with children, the levels of MMPs were positively correlated with the left ventricular function index MMP-8, MMP-9 levels, prompting obesity increases the risk factor for cardiovascular disease, MMPs might participate in the structure remodeling of the left ventricle in obese children, thus caused the change of left ventricular function.correlated. Conclusion: Serum levels of MMPs and TIMPs had changed in school-age obesity children, the levels of MMPs were positively correlated with the left ventricular function index, suggesting obesity increases the risk factor for cardiovascular disease, MMPs may participate in the structure remodeling of the left ventricle in obese children, thus caused the change of left ventricular function.

Key words： obese children serum levels of matrix metalloproteinases serum levels of matrix metallopro-teinases inhibitor echocardiography.

Received: 04 May 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAN Junwei
	LAN Juhong
	LAN Wensheng
	LIU Sheng
	QIAN Lijun.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I1/31

[1] Beaudeux JL, Giral P, Bruckert E, et al. Matrix metalloproteinases inflammation and atherosclerosis: therapeutic perspectives[J]. Clin Chem Lab Med, 2004, 42(2): 121-131.
[2] 黄志伟, 刘玉胜, 耿秀娟, 等. 心力衰竭患儿血清基质金属蛋白酶-2水平变化[J]. 实用儿科临床杂志, 2007, 22(13):988-989.
[3] 庞玉生, 曾红军, 于丽娟, 等. 先天性心脏病并肺动脉高压患儿血清基质金属蛋白酶-1、2与金属蛋白酶组织抑制物-1水平变化的意义[J]. 实用儿科临床杂志, 2008, 23(1):28-30.
[4] Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling[J]. Circulation, 2001, 104(16): 1899-1904.
[5] Souza-Costa DC, Sandrim VC, Lopes LF, et al. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene [J]. Atherosclerosis, 2007, 193(2): 438-444.
[6] Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound[J]. Atherosclerosis, 2006, 187(1): 161-169.
[7] Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.[J]. Am Coll Cardiol, 2005, 46(11): 1978-1985.
[8] Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease[J]. Clin Chim Acta, 2007, 379(1-2): 48-52.
[9] Tuomainen AM, Nyyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men[J]. Arterioscler Thromb Vasc Biol, 2007, 27(12): 2722-2728.
[10] Chavey C, Mari B, Monthouel MN, et al. Matrix metallopro-teinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation[J]. Biol Chem, 2003, 278(14): 11888-11896.
[11] Nair S, Lee YH, Rousseau E, et al. Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians[J]. Diabetologia, 2005, 48(9): 1784-1788.
[12] Croissandeau G, Chretien M, Mbikay M. Involvement of matrix metalloproteinases in the adipose conversion of 3T3-L1 preadipocytes[J]. Biochem, 2002, 364(3): 739-746.
[13] Unal R, Yao-Borengasser A, Varma V, et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone[J]. Clin Endocrinol Metab, 2010,95(6): 2993-3001.
[14] Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin[J]. Biol Chem, 1992, 267(7): 4583-4591.
[15] Martinez ML, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension[J]. Cardiovasc Pharmacol, 2006, 47(1): 117-122.
[16] Glowinska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents[J]. Metabolism, 2007, 56(6):799-805.
[17] Bouloumie A, Sengenes C, Portolan G, et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation[J]. Diabetes, 2001, 95(6): 2993-3001.
[18] Valle M, Martos R, Gascon F, et al. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome[J]. Diabetes Metab, 2005, 31(1): 55-62.
[19] Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponec-tinemia in obesity and type 2 diabetes: close associationwith insulin resistance and hyperinsulinemia[J]. Clin Endocrinol Metab, 2001, 86(5): 1930-1935.
[20] Stefan N, Bunt JC, Salbe AD, et al. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia[J]. Clin Endocrinol Metab, 2002, 87(10): 4652-4656.
[21] Reinehr T, Roth C, Menke T, et al. Adiponectin before and after weight loss in obese children[J]. Clin Endocrinol Metab, 2004, 89(8): 3790-3794.
[22] Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages[J]. Circulation, 2004, 109(17): 2046-2049.
[23] Alpert MA. Management of obesity cardiomyopathy[J]. Am J Med Sci, 2001, 321(4): 237-241.
[24] Mahoney LT, Schieken RM, Clarke WR, et al. Left ventricular mass and exercise responses predict future blood pressure[J].Hypertension, 1988, 12(2): 206-213.
[25] Kinik ST, Varan B, Yildirim SV, et al. The effect of obesity on echocardiographic and metabolic parameters in childhood[J]. Pediatr Endocrinol Metab, 2006, 19(8): 1007-1014.
[26] Kono Y,Yoshinaga M, Oku S, et al. Effect of obesity on echocardiographic parameters in children[J]. Int J Cardiol,1994, 46(1): 7-13.
[27] Sharpe JA, Naylor LH, Jones TW, et al. Impact of obesity on diastolic function in subjects<or=16 years of age[J]. Am J Cardiol, 2006, 98(5): 691-693.
[28] Mehta SK, Holliday C, Hayduk L, et al. Comparison of myocardial function in children with body mass index-es>/=25 versus those<25 kg/m2[J]. Am J Cardiol, 2004, 93(12): 1567-1569.
[29] Uner A, Dogan M, Epcacan Z, et al. The effect of childhood obesity on cardiac functions[J]. Pediatr Endocrinol Metab, 2013, 36(1-2):1-11.
[30] Garavaglia GE, Messerli FH, Nunez BD, et al. Myocardial contractility and left ventricular function in obese patients with essential hypertension[J]. Am J Cardiol, 1988, 62(2): 594-597.
[31] Hijova E. Matrix metalloproteinases: their biological func tions and clinical implications[J]. Am J Bratisl Lek Listy, 2005, 106(3): 127-132.